《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2012年 > 4期

罗格列酮对2型糖尿病患者支架内再狭窄作用的临床研究

来自:中国糖尿病资讯网  编辑:editor|点击数:|2012-04-20

  ·糖尿病临床研究·

  杨娜 丁世芳

  作者单位:430070武汉,广州军区武汉总医院心内科

  【摘要】目的探讨胰岛素增敏剂罗格列酮(RGZ)干预支架内再狭窄(RS)的作用机制。方法选取2009年3~12月我科收治的合并T2DM的冠心病(CHD)患者72例,均择期行选择性冠状动脉造影,必要时行支架安置术。术后随机分为RGZ干预组和Con组。术前和术后第1、3、6个月复查进行常规生化检测,ELISA测定血浆APN、内皮素(ET)含量,统计学分析并记录患者RS事件的发生情况。结果术后3个月,RGZ干预组较Con组血浆APN含量明显升高,血清Ins含量有所下降(P均<0.05);术后6个月,RGZ干预组较Con组血浆ET含量明显降低,FPG水平明显降低(P均<0.05)。结论RGZ可通过升高血浆APN、降低血浆ET含量,对合并T2DM的CHD患者术后RS起到一定的预防作用,其作用随着术后用药时间的延长逐渐显现。

  【关键词】冠心病;糖尿病,2型;罗格列酮;支架内再狭窄;脂联素;内皮素

  doi:10.3969/j.issn.1006-6187.2012.04.012

  The role of rosiglitazone in prevention of in-stent restenosis in type 2 diabetic patientsYANG Na,DING Shi-fang. Department of Cardiology, Wuhan General Hospital of Guangzhou Command,Wuhan 430070,China

  【Abstract】ObjectiveTo observe the role of rosiglitazone in prevention of in-stent restenosis.Methods72 CHD patients with T2DM undergoing selective stent implantation were selected from March to December 2009 in our department,and randomly divided into RGZ intervention group and control group. Plasma APN and ET were detected by ELISA before and 1, 3, 6 months after PCI operation. Data were statistically analyzed and the events of in-stent restensis were recorded.ResultsAfter 3 months, plasma APN levels was higher and serum Ins level was lower (all P<0.05) in RGZ intervention group than in the control group. After 6 months, the plasma ET levels significantly reduced,FPG levels decreased significantly in RGZ group (all P<0.05).ConclusionsRGZ plays a role in prevention of in-stent restenosis by increasing plasma APN and decreasing plasma ET in CHD patients with T2DM after stent implantation.

  【Key words】Coronary heart disease;Diabetes mellitus, type 2;Rosiglitazone;In-stent restenosis;Adiponectin;Endothelin

上一篇:肥胖者颈动脉内膜中层厚度和血铁蛋白、Apelin及胰岛素抵抗关系的研究 下一篇:地特胰岛素控制2型糖尿病围手术期血糖的临床应用